S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia
Public ClinicalTrials.gov record NCT00723658. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
S0629, Observational Study of Asymptomatic Waldenstrom's Macroglobulinemia and Phase II Study of Tandem Autologous Transplant and Maintenance Treatment for Patients With Symptomatic Disease
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
RATIONALE: Sometimes the cancer may not need treatment until it progresses. In this case, observation may be sufficient. Giving combination chemotherapy together with bortezomib, thalidomide, and rituximab before an autologous peripheral stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them. Giving colony-stimulating factors, such as G-CSF, helps stem cells move from the bone marrow to the blood so they can be collected and stored. More chemotherapy is then given to prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy. PURPOSE: This observational and phase II trial is studying how well giving combination chemotherapy together with bortezomib, thalidomide, and rituximab followed by two autologous peripheral blood stem cell transplants works in treating patients with Waldenstrom macroglobulinemia.
Study identification
- NCT ID
- NCT00723658
- Recruitment status
- Withdrawn
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- Not listed
Conditions and interventions
Conditions
Interventions
- rituximab Biological
- bortezomib Drug
- carmustine Drug
- cisplatin Drug
- cyclophosphamide Drug
- cytarabine Drug
- dexamethasone Drug
- doxorubicin hydrochloride Drug
- etoposide Drug
- melphalan Drug
- thalidomide Drug
- autologous-autologous tandem hematopoietic stem cell transplantation Procedure
- peripheral blood stem cell transplantation Procedure
Biological · Drug · Procedure
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 2008 (Type not available)
- Primary completion
- May 2010 (Actual)
- Completion
- Not listed
- Last update posted
- Mar 6, 2015
Started 2008
United States locations
- U.S. sites
- 29
- U.S. states
- 5
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center | Hartford | Connecticut | 06105 | — |
| St. Francis Hospital and Health Centers - Beech Grove Campus | Beech Grove | Indiana | 46107 | — |
| Reid Hospital & Health Care Services | Richmond | Indiana | 47374 | — |
| Lawrence Memorial Hospital | Lawrence | Kansas | 66044 | — |
| Wesley Medical Center | Wichita | Kansas | 67214 | — |
| Saint Joseph Mercy Cancer Center | Ann Arbor | Michigan | 48106-0995 | — |
| CCOP - Michigan Cancer Research Consortium | Ann Arbor | Michigan | 48106 | — |
| Oakwood Cancer Center at Oakwood Hospital and Medical Center | Dearborn | Michigan | 48123-2500 | — |
| Barbara Ann Karmanos Cancer Institute | Detroit | Michigan | 48201-1379 | — |
| Genesys Hurley Cancer Institute | Flint | Michigan | 48503 | — |
| Hurley Medical Center | Flint | Michigan | 48503 | — |
| Van Elslander Cancer Center at St. John Hospital and Medical Center | Grosse Pointe Woods | Michigan | 48236 | — |
| Foote Memorial Hospital | Jackson | Michigan | 49201 | — |
| Sparrow Regional Cancer Center | Lansing | Michigan | 48912-1811 | — |
| St. Mary Mercy Hospital | Livonia | Michigan | 48154 | — |
| St. Joseph Mercy Oakland | Pontiac | Michigan | 48341-2985 | — |
| Mercy Regional Cancer Center at Mercy Hospital | Port Huron | Michigan | 48060 | — |
| Seton Cancer Institute at Saint Mary's - Saginaw | Saginaw | Michigan | 48601 | — |
| St. John Macomb Hospital | Warren | Michigan | 48093 | — |
| Grandview Hospital | Dayton | Ohio | 45405 | — |
| Good Samaritan Hospital | Dayton | Ohio | 45406 | — |
| David L. Rike Cancer Center at Miami Valley Hospital | Dayton | Ohio | 45409 | — |
| CCOP - Dayton | Dayton | Ohio | 45420 | — |
| Blanchard Valley Medical Associates | Findlay | Ohio | 45840 | — |
| Middletown Regional Hospital | Franklin | Ohio | 45005-1066 | — |
| Charles F. Kettering Memorial Hospital | Kettering | Ohio | 45429 | — |
| UVMC Cancer Care Center at Upper Valley Medical Center | Troy | Ohio | 45373-1300 | — |
| Clinton Memorial Hospital | Wilmington | Ohio | 45177 | — |
| Ruth G. McMillan Cancer Center at Greene Memorial Hospital | Xenia | Ohio | 45385 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00723658, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 6, 2015 · Synced Oct 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00723658 live on ClinicalTrials.gov.